BioSpace News Archive

Alentis Therapeutics (“Alentis”) announced today that the US Food and Drug Administration (FDA) has granted Fast Track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1-positive HNSCC.

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has achieved key milestones in its R&D collaboration with Labcorp, a global leader of innovative and comprehensive laboratory services, aimed at driving innovation in the development and validation of cell and gene therapies.

Abata Therapeutics today announced its second development candidate, ABA-201, which has the potential to be a disease-modifying Treg cell therapy for patients with type 1 diabetes (T1D) who have remaining beta (β) cell function.

Bionoid Pharma, Inc. is pleased to announce the extension of the effective period of a Letter of Intent, along with its exclusivity provisions, with Global Alerts Corp., as initially disclosed on March 22, 2023.

Jaguar Health, Inc., a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal prescription medicines, announced it has engaged B2i Digital to execute an innovative digital investor engagement and awareness program.

Can-Fite BioPharma Ltd. announced it plans to develop its lead drug candidate, Piclidenoson, for the treatment of Lowe Syndrome based on recent efficacy findings by Dr. Antonella De Matteis, Professor of Biology, Department of Molecular Medicine and Medical Biotechnology at the University of Naples Federico II, and Program Coordinator of the Cell Biology and Disease Mechanisms at The Telethon Institute of Genetics and Medicine in Italy.

Aprea Therapeutics, Inc., a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, announced it has appointed Dr. Jean-Pierre Bizzari to its Board of Directors and is naming Dr. Richard Peters as its new Chairman of the Board.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that the Aptose management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, in New York City.

Societal CDMO, Inc. announced the pricing of its previously announced underwritten public offering of 20,750,000 shares of its common stock at a public offering price of $0.40 per share of common stock, for gross proceeds of $8.3 million, before underwriting discounts and commissions and offering expenses.

Intelligent Bio Solutions Inc., a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for its fiscal fourth quarter and full-year ended June 30, 2023, and provided a business update.